Femasys Inc. enters its May 15 earnings event having endured another rough week — down 6.7% on Tuesday alone and 5.6% over the past five days, bringing the stock to $0.38. The tension heading into the release is straightforward: the share price has lost ground for a month, yet short sellers have been pulling back, and borrowing costs have fallen sharply. Those two signals are pointing in opposite directions.
Positioning tells a more relaxed story than the price action suggests. Short interest has dropped roughly 9% over the past week to 3.1% of the free float — a meaningful retreat from early April levels near 4% of float. The move mirrors a broader unwind: shorts are down almost 25% over the past month. Borrowing costs have also eased significantly, falling to 6.5% annualised from above 10% a month ago, and down 68% over 30 days. Availability in the lending pool is ample, with shares freely accessible for new short positions. The ORTEX short score of 52.3 — down from 56.6 on May 8 — reflects the same softening. This is not a crowded short.
The Street is uniformly bullish in rating but increasingly divided on where the stock eventually lands. All covering analysts carry Buy ratings. Lake Street initiated in March with a $1.50 target — the most recent action, and the most cautious. That sits well above the current $0.38 price, yet is a fraction of HC Wainwright's $8.00 target. The mean target of approximately $3.17 implies significant upside on paper, but the dispersion between analysts is wide, and targets have been cut repeatedly over the past year. The bull case centres on FemBloc commercialisation — European revenue recognition was flagged as possible in the first half of 2026 — while bears point to the need for roughly $60 million in additional financing to sustain operations to 2038, plus competition and clinical execution risk. EPS momentum ranks in the bottom third of the universe, and EPS surprise scores near the bottom decile, suggesting estimates have been consistently missed.
Institutional ownership is thinly spread. Dauntless Investment Group holds the largest stake at 9.8% of shares, having added 2 million shares in the quarter to December 2025. Vanguard added 464,000 shares in the March 2026 quarter, bringing its holding to 2.3% of shares. Notably, PharmaCyte Biotech holds a 695,537-share position, disclosed in March 2026 as a new entry. These are small-cap specialist and passive buyers rather than activist conviction. The most recent insider trades on record date from August 2025, when the CEO and CFO both made modest open-market purchases below $0.52 — a signal of alignment, but the data is now stale.
The earnings history adds useful context ahead of Thursday's event. The last four prints produced moves of -10%, +3%, +11%, and -20% on the first day. The range is wide and the direction has been inconsistent. The two largest reactions were both negative. A May 8 announcement already clipped the stock 10%, so investors are approaching this week's event with recent volatility fresh in mind. Close peer ARAY fell 32% over the past week, illustrating the fragility of small health-care equipment names in the current tape. NPCE dropped 7.3% on the week; IDXX lost 5.2%.
What to watch is whether the May 15 print carries any update on FemBloc European commercial timing — the one concrete catalyst the bull case depends on — and whether the financing runway commentary shifts from the bearish $60 million figure that has been hanging over the story.
See the live data behind this article on ORTEX.
Open FEMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
